Short answer
Amgen (AMGN) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 results cover three months ended March 31, 2026, with the earnings release issued April 30, 2026.
Amgen 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results cover three months ended March 31, 2026, with the earnings release issued April 30, 2026
- Exhibit 99.1 contains unaudited operating results and financial position details
- Non-GAAP metrics include EPS, operating income, margin, tax rate, expenses, and free cash flow
- Non-GAAP adjustments primarily exclude acquisition-related charges, restructuring costs, investment gains or losses, and legal items
- Investors should compare GAAP results with reconciled non-GAAP figures, especially given acquisition and restructuring adjustments
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amgen 8-K filings
Get the next AMGN 8-K as it lands
Follow AMGN for push alerts, or ask the research agent what this filing means.